Truist Reiterates Buy Rating on Viridian Therapeutic (VRDN) Following Veligrotug's FDA approval
Tweet Send to a Friend
Truist Securities analyst Greg Renza reiterated a Buy rating and $35.00 price target on Viridian Therapeutic (NASDAQ: VRDN).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
